Trademark: AMGEN
Put your brand on the blockchain and timestamp its proof of existence at wikitrademarks.io
Mark Identification
Proof of use for AMGEN
We do not have any records of a proof of use for AMGEN at this moment.
Possible trademark infringements of AMGEN
Basic Information about AMGEN
- Serial Number
- 78736482
- Filing Date
- 19 Oct 2005
- Registration Number
- 3921146
- Registration Date
- 15 Feb 2011
- Mark Drawing Code
- 4
Classifications
Declare the trademark use of AMGEN on the blockchain with WikiTrademarks.io.
- First use of AMGEN anywhere
- AMGEN was first used on 31 Mar 1984 for the primary classification of goods and services, international, 005 (Pharmaceuticals)
- First use in commerce
- There is no first use of this trademark in commerce detected yet.
- Status Code
- 6
- International Code
- 005
- US Codes
- 006; 018; 044; 046; 051; 052
Who owns AMGEN?
Correspondent
- Timothy J. Gaul
- Amgen Inc.
- Trademark Operations MS 28-5-A
- One Amgen Center Drive
Recent News about AMGEN
Amgen v. Sanofi: Seven Months In, Has Anything About Patent Enablement Changed? Tweet this
Amgen is the Answer to Alice Tweet this
This week on MIP: Amgen biosimilar ban, new UPC judges Tweet this
SCOTUS Ushers in New Era of Enablement Law in Amgen Ruling Tweet this
The Truth Leaks Out: Justices Struggle with the Science, Sanofi Welcomes End to Functional Genus Claims in Amgen Oral Arguments Tweet this
What I’ll Be Watching for in the Amgen Oral Arguments Tweet this
Amgen Reply Brief Addresses Mischaracterizations by Sanofi, U.S. Government on Proper Enablement Inquiry for Genus Claims Tweet this
Amici Filings in Amgen Encourage the Supreme Court to Correct the Federal Circuit’s ‘Unworkable’ Enablement Standard Tweet this
Juno Asks Supreme Court to Reconsider Denial of Petition on Section 112 Question in Light of Amgen Review Tweet this
SCOTUS Takes on Scope of Enablement Inquiry in Amgen v. Sanofi: Implications for Pharma/ Biotech and Beyond Tweet this
Supreme Court Grants Two IP Cases, Including Amgen v. Sanofi on Enablement Tweet this
Amgen Says Solicitor General’s ‘Disagreement With Everyone’ Further Supports SCOTUS Review of Legal Standard for Enablement Tweet this
Other Barks & Bites for Friday, October 7: OSTP Publishes AI Bill of Rights Blueprint, Amgen Files Supplement Brief on Enablement Appeal, and Longtime Register of Copyrights Peters Passes Away Tweet this
CAFC Denies Amgen Petition to Reconsider Enablement Test for Biotech Patents Tweet this
Put your brand on the blockchain and timestamp its proof of existence at Wikitrademarks.io